Alice Kornblith - Academia.edu (original) (raw)

Uploads

Papers by Alice Kornblith

Research paper thumbnail of Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)

Journal of Geriatric Oncology, 2012

Purpose-The purpose of this study was to assess the impact of aging, comorbidities and symptoms o... more Purpose-The purpose of this study was to assess the impact of aging, comorbidities and symptoms on physical function in patients surviving 20 years since adjuvant treatment for breast cancer. Patients & Methods-Patients were originally treated on CALGB 7581 (from 1975-1980), a randomized trial of three adjuvant therapies and reassessed (153 of 193 eligible survivors) 20 years from the onset of therapy for physical function and symptoms by the EORTC QLQ-C30 and comorbidities by the OARS questionnaire. Results-The average age at reassessment was 64.5 years. 66% of patients had at least two comorbidities and 22% had four or more, but relatively little interference with activities. Older patients had greater multimorbidity. Physical function was generally high and comparable to matched population norms. Older patients had greater difficulty with strenuous activities. For every increase in number of comorbidities, physical function score decreased by 5.1 (p<.001). Symptoms were also frequent (80%) and correlated strongly with decreases in function (0-100u scale) (p <.001), to an even greater degree than comorbidities. Conclusion-Very long-term cancer survivors have changes in physical function and symptoms largely consistent with their aging suggesting that the impact of cancer and its treatment is attenuated over time and largely replaced by the impact of age-related comorbidities and functional decline.

Research paper thumbnail of Adjuvant Chemotherapy In Older Women With Early-Stage Breast Cancer

… England Journal of …, 2009

Hyman B. Muss, MD, Donald A. Berry, Ph.D., Constance T. Cirrincione, MS, Maria Theodoulou, MD, An... more Hyman B. Muss, MD, Donald A. Berry, Ph.D., Constance T. Cirrincione, MS, Maria Theodoulou, MD, Ann M. Mauer, MD, Alice B. Kornblith, Ph.D., Ann H. Partridge, MD, MPH, Lynn G. Dressler, Ph.D., Harvey J. Cohen, MD, Heather P. Becker, Patricia A. Kartcheske, BS, ...

Research paper thumbnail of Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance)

Journal of oncology practice / American Society of Clinical Oncology, 2014

We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall surviva... more We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall survival (OS) in older women with early-stage breast cancer receiving adjuvant chemotherapy. Cancer and Leukemia Group B 49907 (Alliance) randomly assigned women ≥ 65 years old with stages I-III breast cancer to standard adjuvant chemotherapy or capecitabine. We reviewed data from 329 women who participated in the quality of life companion study CALGB 70103 and completed the Physical Health Subscale of the Older American Resources and Services Questionnaire. This questionnaire captures data on 14 comorbid conditions and the degree to which each interferes with daily activities. A comorbidity burden score was computed by multiplying the total number of conditions by each condition's level of interference with function. Outcomes were grade 3 to 5 toxicity, TTR, and OS. Logistic regression was used to evaluate associations between comorbidity and toxicity, and Cox proportional hazards models f...

Research paper thumbnail of Impact of age, comorbidity and symptoms on physical function in long-term breast cancer survivors (CALGB 70803)

Journal of Geriatric Oncology, 2012

Purpose-The purpose of this study was to assess the impact of aging, comorbidities and symptoms o... more Purpose-The purpose of this study was to assess the impact of aging, comorbidities and symptoms on physical function in patients surviving 20 years since adjuvant treatment for breast cancer. Patients & Methods-Patients were originally treated on CALGB 7581 (from 1975-1980), a randomized trial of three adjuvant therapies and reassessed (153 of 193 eligible survivors) 20 years from the onset of therapy for physical function and symptoms by the EORTC QLQ-C30 and comorbidities by the OARS questionnaire. Results-The average age at reassessment was 64.5 years. 66% of patients had at least two comorbidities and 22% had four or more, but relatively little interference with activities. Older patients had greater multimorbidity. Physical function was generally high and comparable to matched population norms. Older patients had greater difficulty with strenuous activities. For every increase in number of comorbidities, physical function score decreased by 5.1 (p<.001). Symptoms were also frequent (80%) and correlated strongly with decreases in function (0-100u scale) (p <.001), to an even greater degree than comorbidities. Conclusion-Very long-term cancer survivors have changes in physical function and symptoms largely consistent with their aging suggesting that the impact of cancer and its treatment is attenuated over time and largely replaced by the impact of age-related comorbidities and functional decline.

Research paper thumbnail of Adjuvant Chemotherapy In Older Women With Early-Stage Breast Cancer

… England Journal of …, 2009

Hyman B. Muss, MD, Donald A. Berry, Ph.D., Constance T. Cirrincione, MS, Maria Theodoulou, MD, An... more Hyman B. Muss, MD, Donald A. Berry, Ph.D., Constance T. Cirrincione, MS, Maria Theodoulou, MD, Ann M. Mauer, MD, Alice B. Kornblith, Ph.D., Ann H. Partridge, MD, MPH, Lynn G. Dressler, Ph.D., Harvey J. Cohen, MD, Heather P. Becker, Patricia A. Kartcheske, BS, ...

Research paper thumbnail of Comorbidity, chemotherapy toxicity, and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361004 (alliance)

Journal of oncology practice / American Society of Clinical Oncology, 2014

We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall surviva... more We evaluated associations among comorbidity, toxicity, time to relapse (TTR), and overall survival (OS) in older women with early-stage breast cancer receiving adjuvant chemotherapy. Cancer and Leukemia Group B 49907 (Alliance) randomly assigned women ≥ 65 years old with stages I-III breast cancer to standard adjuvant chemotherapy or capecitabine. We reviewed data from 329 women who participated in the quality of life companion study CALGB 70103 and completed the Physical Health Subscale of the Older American Resources and Services Questionnaire. This questionnaire captures data on 14 comorbid conditions and the degree to which each interferes with daily activities. A comorbidity burden score was computed by multiplying the total number of conditions by each condition's level of interference with function. Outcomes were grade 3 to 5 toxicity, TTR, and OS. Logistic regression was used to evaluate associations between comorbidity and toxicity, and Cox proportional hazards models f...